diltiazem has been researched along with prednisone in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 12 (57.14) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Li, EK; Tam, LS | 1 |
| Imani, S; Jusko, WJ; Steiner, R | 1 |
| Hashimoto, Y; Tashima, K; Uchino, M; Uyama, E; Yonehara, T | 1 |
| Callen, JP; Weinel, S | 1 |
| Burman, KD; Carroll, NM; Devdhar, M; Popoveniuc, G; Sharma, M; Wartofsky, L; Wexler, JA | 1 |
| Jiang, X; Li, L; Liu, D; Wang, S; Yi, Q | 1 |
| Gual Capllonch, F; Sancho Cía, JM; Triguero Moreno, A | 1 |
1 review(s) available for diltiazem and prednisone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
20 other study(ies) available for diltiazem and prednisone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Cyclophosphamide; Diltiazem; Female; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Prednisone; Vasodilator Agents; Warfarin | 1998 |
Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers.
Topics: Administration, Oral; Adolescent; Adult; Calcium Channel Blockers; Cytochrome P-450 Enzyme System; Diltiazem; Drug Interactions; Humans; Immunosuppressive Agents; Lymphocyte Count; Middle Aged; Prednisolone; Prednisone; T-Lymphocytes | 1999 |
Susac's syndrome: beneficial effects of corticosteroid therapy in a Japanese case.
Topics: Adult; Anti-Inflammatory Agents; Asian People; Asthma; Ataxia; Brain; Cognition Disorders; Confusion; Diagnosis, Differential; Diltiazem; Drug Therapy, Combination; Hearing Loss, Bilateral; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis; Papilledema; Prednisone; Reflex, Abnormal; Retinal Artery; Retinal Artery Occlusion; Skin Diseases, Vascular; Syndrome; Ticlopidine; Vasculitis, Central Nervous System | 2001 |
Calcinosis cutis complicating adult-onset dermatomyositis.
Topics: Adult; Calcinosis; Dermatomyositis; Diagnosis, Differential; Diltiazem; Drug Administration Schedule; Female; Humans; Immunoglobulins; Immunosuppressive Agents; Prednisone | 2004 |
Graves' disease and thymic hyperplasia: the relationship of thymic volume to thyroid function.
Topics: Adrenergic beta-Antagonists; Adult; Anti-Inflammatory Agents; Antithyroid Agents; Calcium Channel Blockers; Diltiazem; Female; Graves Disease; Humans; Male; Methimazole; Middle Aged; Organ Size; Prednisone; Propanolamines; Propranolol; Radiography; Thymus Gland; Thymus Hyperplasia; Thyroidectomy; Thyrotoxicosis; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine; Young Adult | 2010 |
A case of juvenile dermatomyositis with severe calcinosis and successful treatment with prednisone and diltiazem.
Topics: Anti-Inflammatory Agents; Calcinosis; Calcium Channel Blockers; Child; Dermatomyositis; Diltiazem; Drug Therapy, Combination; Humans; Liver; Male; Prednisone; Radiography; Treatment Outcome | 2011 |
Secondary prophylaxis of an acute coronary syndrome during rituximab infusion.
Topics: Acute Coronary Syndrome; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Clopidogrel; Cyclophosphamide; Diltiazem; Doxorubicin; Female; Humans; Lymphoma, Follicular; Platelet Aggregation Inhibitors; Prednisone; Rituximab; Secondary Prevention; Vincristine | 2020 |